Risankizumab for 12 Weeks Leads to Remission in Crohn’s Trials

Risankizumab for 12 Weeks Leads to Remission in Crohn’s Trials

283283

Risankizumab for 12 Weeks Leads to Remission in Crohn’s Trials

Treatment with risankizumab for 12 weeks (three months) induced both clinical and endoscopic remission in people with Crohn’s disease, a type of inflammatory bowel disease (IBD), new Phase 3 clinical trial data show. “Helping patients achieve both clinical remission and endoscopic response early is paramount when treating Crohn’s disease,” Remo Panaccione, MD, professor of medicine and director of the IBD unit at the University of Calgary, said in a press release. Panaccione noted that patients…

You must be logged in to read/download the full post.